Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization

A recent clinical trial of a T-cell-based AIDS vaccine delivered with recombinant adenovirus type 5 (rAd5) vectors showed no efficacy in lowering viral load and was associated with increased risk of human immunodeficiency virus type 1 (HIV-1) infection. Preexisting immunity to Ad5 in humans could th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cheng, Cheng, Gall, Jason G. D., Nason, Martha, King, C. Richter, Koup, Richard A., Roederer, Mario, McElrath, M. Juliana, Morgan, Cecilia A., Churchyard, Gavin, Baden, Lindsey R., Duerr, Ann C., Keefer, Michael C., Graham, Barney S., Nabel, Gary J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology (ASM) 2010
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2798414/
https://ncbi.nlm.nih.gov/pubmed/19846512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00866-09
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares